Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib in BRCA1/2-mutant Relapsed Ovarian Cancer
NCT03509636Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluzoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Hengrui. Primary endpoint: Objective Response Rate. Started Apr 2018; status: completed.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03509636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509636.